CD274 and non-small cell lung carcinoma: Dhar et al. reported that the proportion of PD-L1-positive CTCs from one patient with NSCLC who received avelumab treatment and achieved long-term efficacy for at least more than 600 days was always high (between 80.6% and 100%) during serial evaluation every few months until approximately day 350 [29].